Q1 EPS Estimates for Veeva Systems Raised by Zacks Research

Veeva Systems Inc. (NYSE:VEEV) – Zacks Research lifted their Q1 2026 earnings estimates for Veeva Systems in a research note issued on Wednesday, March 26th. Zacks Research analyst R. Department now expects that the technology company will earn $1.21 per share for the quarter, up from their previous forecast of $1.08. The consensus estimate for Veeva Systems’ current full-year earnings is $4.35 per share. Zacks Research also issued estimates for Veeva Systems’ FY2026 earnings at $5.07 EPS, Q3 2027 earnings at $1.42 EPS, Q4 2027 earnings at $1.43 EPS, FY2027 earnings at $5.53 EPS and FY2028 earnings at $6.79 EPS.

Other equities research analysts also recently issued research reports about the company. Mizuho assumed coverage on Veeva Systems in a report on Wednesday, December 4th. They issued an “outperform” rating and a $275.00 target price on the stock. Canaccord Genuity Group boosted their target price on Veeva Systems from $210.00 to $270.00 and gave the stock a “hold” rating in a research note on Friday, December 6th. Needham & Company LLC reaffirmed a “buy” rating and set a $270.00 price target on shares of Veeva Systems in a report on Thursday, March 6th. JPMorgan Chase & Co. raised their target price on shares of Veeva Systems from $218.00 to $249.00 and gave the company a “neutral” rating in a research report on Thursday, March 20th. Finally, KeyCorp cut their price objective on Veeva Systems from $285.00 to $255.00 and set an “overweight” rating on the stock in a report on Wednesday, January 8th. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and sixteen have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $256.52.

Veeva Systems Trading Down 1.4 %

Shares of Veeva Systems stock opened at $234.10 on Monday. The company has a market cap of $38.01 billion, a PE ratio of 57.80, a price-to-earnings-growth ratio of 1.89 and a beta of 0.88. The company has a 50 day moving average of $231.62 and a 200-day moving average of $222.87. Veeva Systems has a 1-year low of $170.25 and a 1-year high of $258.93.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Cardinal Capital Management boosted its stake in shares of Veeva Systems by 0.3% in the 4th quarter. Cardinal Capital Management now owns 15,727 shares of the technology company’s stock valued at $3,307,000 after purchasing an additional 44 shares in the last quarter. Johnson Financial Group Inc. boosted its position in Veeva Systems by 22.7% during the fourth quarter. Johnson Financial Group Inc. now owns 238 shares of the technology company’s stock valued at $56,000 after buying an additional 44 shares during the period. MassMutual Private Wealth & Trust FSB grew its stake in shares of Veeva Systems by 72.5% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 119 shares of the technology company’s stock valued at $25,000 after buying an additional 50 shares during the last quarter. Patriot Financial Group Insurance Agency LLC increased its holdings in shares of Veeva Systems by 0.7% in the fourth quarter. Patriot Financial Group Insurance Agency LLC now owns 6,975 shares of the technology company’s stock worth $1,467,000 after buying an additional 51 shares during the period. Finally, CHICAGO TRUST Co NA lifted its stake in shares of Veeva Systems by 2.9% in the 4th quarter. CHICAGO TRUST Co NA now owns 1,880 shares of the technology company’s stock valued at $395,000 after acquiring an additional 53 shares during the last quarter. Institutional investors and hedge funds own 88.20% of the company’s stock.

Veeva Systems Company Profile

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States.